Indications
Pemetrexed Ever Pharma Ever Pharma is indicated in non-squamous non-small cell lung cancer (NSCLC) in the following settings: in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic non-squamous NSCLC who have no EGFR or ALK genomic tumor aberrations; in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous NSCLC; as a single agent for the maintenance treatment of patients with locally advanced or metastatic non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy; and as a single agent for the treatment of patients with recurrent, metastatic non-squamous NSCLC after prior chemotherapy. Limitations of use: Pemetrexed Ever Pharma Ever Pharma is not indicated for the treatment of patients with squamous cell non-small cell lung cancer. In mesothelioma, Pemetrexed Ever Pharma Ever Pharma is indicated, in combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. In vitro studies show that Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, Pemetrexed is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of of TS and GARFT.
Pregnancy & Breastfeeding
Pemetrexed can cause fetal harm when given to a pregnant woman, and no data are available on its use in this population; pregnant women should be told about this potential risk to the fetus. It is not known whether Pemetrexed or its metabolites pass into human milk, and their effects on a breastfed infant or on milk production are unknown. Because of the potential for serious adverse reactions in breastfed infants, women should not breastfeed during treatment with Pemetrexed and for one week after the last dose.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Dosage Reference
⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.